Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00467987 · ClinicalTrials.gov registry record · NA
Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism
A NA study, sponsored by University at Buffalo.
- Terminated
- Registry status
- NA
- Development phase
- 47
- Enrollment target
NCT00467987 is a NA study that was terminated before completion, run by University at Buffalo. The registered enrollment target is 47 participants.
The verdict
NCT00467987, a NA study, was terminated before completion, sponsored by University at Buffalo.
- TERMINATED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effects of testosterone deficiency in men with diabetes on atherogenesis, inflammation, cardiovascular Risk factors And adiposity .
Interventions
- DRUG placebo
- DRUG androgel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2007-06-01 |
| Est. Completion | 2018-10-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00467987
The ClinicalTrials.gov registry entry for NCT00467987 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00467987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00467987 about?
NCT00467987 is a clinical study titled "Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism". The purpose of this study is to examine the effects of testosterone deficiency in men with diabetes on atherogenesis, inflammation, cardiovascular Risk factors And adiposity .
What is the current status of trial NCT00467987?
This trial is currently terminated. It is a NA study. The enrollment target is 47 participants. The study started on 2007-06-01. Estimated completion is 2018-10-11.
What interventions are being tested in trial NCT00467987?
The interventions under investigation include: placebo (DRUG), androgel (DRUG).
Who is sponsoring clinical trial NCT00467987?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.